Elekta wins order for 3-D brain mapping MEG technology from Max Planck
Institute
16 Oct 2006 Stockholm, Sweden. The Max Planck Institute for Human
Cognitive and Brain Science (MPI CBS) in Leipzig, Germany has ordered a
Neuromag system from Swedish company Elekta (STO:EKTAB). The Elekta Neuromag
uses magnetoencephalography (MEG) technology to map the brain.
MPI CBS will upgrade its facilities and replace its current MEG equipment
with the Neuromag system. Neurosurgeons, neurologists and psychiatrists will
be able to non-invasively register nerve cell activity in the brain in real
time, better and more accurate than before. Improvements are further
enhanced by the innovative MaxFilter software that filters all magnetic
interferences and artifacts, both internal and external, and provides an
analysis with more reliable data. MEG technology is for many reasons
regarded as the most efficient method for tracking brain activity in
real-time.
Compared to EEG, MEG has unique sensitivity capabilities. MEG also offers
functional mapping information and measurement of brain activity in real
time, unlike Computer Tomography (CT) and Magnetic Resonance Imaging (MRI
and fMRI) which only provide structural, anatomical and metabolic
information. As an important complement to these technologies, MEG increases
the ability to understand brain activity and to improve treatment of
functional disorders in the brain. The MPI CBS, a research institute of
the world famous Max-Planck Gesellschaft, is performing fundamental research
revolving around human cognitive abilities and cerebral processes. Ongoing
research look into the perception of language, music, actions and their
outcome, the planning and generation of language and activity, and the
interaction between, and common functional principles of, generation and
perception in various cognitive fields. “Elekta is and has always been
dedicated to fighting serious disease and we can see a great untapped
potential in MEG. MEG is already a proven technology with great value in
brain research. Currently we see much exciting development going on in the
field of clinical applications and Elekta is fully committed to leading this
development and bring its possibilities into clinical use, benefiting
patients all over the world,” says Tomas Puusepp, President and CEO of
Elekta. “As the only MEG vendor on the market with the financial stability
needed to be committed to the long-term development of MEG technology, we
are alone in being able to offer long-term relationships and ensure future
development of the platform and its applications, thereby securing the
customers' investment.” To top
|
|